DrugPatentWatch Database Preview
ENBREL Drug Profile
Summary for Tradename: ENBREL
| Patents: | 327 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 2 |
| Drug Prices: | Drug price information for ENBREL |
| Recent Clinical Trials: | See clinical trials for ENBREL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ENBREL |
Recent Clinical Trials for ENBREL
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Academic Medical Organization of Southwestern Ontario | Phase 4 |
| Lawson Health Research Institute | Phase 4 |
| Psoriasis Treatment Center of Central New Jersey | Phase 4 |
Recent Litigation for ENBREL
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| CELGENE CORPORATION v. HETERO LABS LIMITED | 2019-07-16 |
| CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. | 2019-07-12 |
| CELGENE CORPORATION v. CIPLA LIMITED | 2019-07-03 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Dr. Reddy's Laboratories, Inc. | 2018-08-03 |
Pharmacology for ENBREL
| Mechanism of Action | Tumor Necrosis Factor Receptor Blocking Activity |
Company Disclosures: US Patents for ENBREL
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2012-03-07 | RX | Orphan | company |
| Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2014-02-25 | RX | Orphan | company |
| Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2009-09-05 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for ENBREL
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Massachusetts Eye and Ear Infirmary (Boston, MA) | 2034-06-16 | RX | Orphan | search |
| Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Knopp Biosciences LLC (Pittsburgh, PA) | 2033-08-13 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ENBREL
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 369862 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2008131041 | Start Trial |
| Mexico | 2007000842 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ENBREL
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| CA 2015 00021 | Denmark | Start Trial | PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141021 |
| 92692 | Luxembourg | Start Trial | PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023 |
| PA2008014 | Lithuania | Start Trial | PRODUCT NAME: ABATACEPTUM; REGISTRATION NO/DATE: EU/1/07/389/001, 2007 05 21, EU/1/07/389/002, 2007 05 21, EU/1/07/389/003 20070521 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
